A BILL 
To amend the Federal Food, Drug, and Cosmetic Act to 
clarify the conditions under which the Secretary of 
Health and Human Services can approve generic drug 
applications with labeling temporarily different than the 
brand name drug, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Enhanced Access to 
4
Affordable Medicines Act of 2022’’. 
5
06:20 Apr 07, 2022
H6973
2 
•HR 6973 IH
SEC. 2. CLARIFYING THE CONDITIONS OF GENERIC DRUG 
1
APPLICATION APPROVAL FOR LAST-MINUTE 
2
BRAND NAME DRUG LABELING CHANGES. 
3
Section 505(j)(10)(A) of the Federal Food, Drug, 
4
and Cosmetic Act (21 U.S.C. 355(j)(10)(A)) is amended 
5
by striking clauses (i) through (iv) and inserting the fol-
6
lowing: 
7
‘‘(i) the application is otherwise eligible for ap-
8
proval under this subsection except that— 
9
‘‘(I)(aa) the listed drug has an active pat-
10
ent, the listed drug has an active exclusivity pe-
11
riod, or there is a delay in approval as de-
12
scribed in paragraph (5)(B)(iii); and 
13
‘‘(bb) a revision to the labeling of the listed 
14
drug has been approved by the Secretary within 
15
90 days of expiration of a patent, exclusivity 
16
period, or delay in approval referenced in item 
17
(aa); or 
18
‘‘(II) a revision to the labeling of the listed 
19
drug has been approved by the Secretary, with-
20
in 90 days of when the application is otherwise 
21
eligible for approval under this subsection; 
22
‘‘(ii) the sponsor of the application agrees to 
23
submit revised labeling for the drug that is the sub-
24
ject of the application not later than 60 days after 
25
06:20 Apr 07, 2022
H6973
3 
•HR 6973 IH
approval under this subsection of the application; 
1
and 
2
‘‘(iii) the labeling revision described under 
3
clause (i) does not include a change to the ‘Warn-
4
ings’ section of the labeling.’’. 
5
Æ 
06:20 Apr 07, 2022
H6973
